Published in Immun Ageing on November 12, 2004
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing (2013) 1.08
Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis (2006) 1.04
Alzheimer's disease: new diagnostic and therapeutic tools. Immun Ageing (2008) 0.79
Is immunotherapy an effective treatment for Alzheimer's disease? Immun Ageing (2004) 0.77
Current experimental therapy for Alzheimer's disease. Curr Neuropharmacol (2007) 0.76
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 3.93
A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2001) 3.28
Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med (2001) 3.10
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest (2004) 2.52
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 2.38
Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A (1997) 2.35
Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 2.12
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol (2002) 1.68
Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. Trends Pharmacol Sci (2004) 1.41
The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci (2003) 1.39
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
Therapeutic antibodies: magic bullets hit the target. Nature (2002) 1.04
New technologies in therapeutic antibody development. Curr Opin Pharmacol (2003) 1.00
A safer vaccine for Alzheimer's disease? Neurobiol Aging (2002) 0.93
The effect of age on B cell development and humoral immunity. Springer Semin Immunopathol (2002) 0.86
Age-related differences in the immune response to immunization with human Abeta42 peptide. J Gerontol A Biol Sci Med Sci (2002) 0.79
Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin Biol Ther (2004) 0.78